Genetically Determined Chronic Low-Grade Inflammation and Hundreds of Health Outcomes in the UK Biobank and the FinnGen Population: A Phenome-Wide Mendelian Randomization Study
BackgroundC-reactive protein (CRP) has been used as a biomarker of chronic low-grade inflammation in observational studies. We aimed to determine whether genetically determined CRP was associated with hundreds of human phenotypes to guide anti-inflammatory interventions.MethodsWe used individual data from the UK Biobank to perform a phenome-wide two-stage least squares (2SLS) Mendelian randomization (MR) analysis for CRP with 879 diseases. Summary-level data from the FinnGen consortium were utilized to perform phenome-wide two-sample MR analysis on 821 phenotypes. Systematic two-sample MR methods included MR-IVW, MR-WME, MR-Mod, and MR-PRESSO as sensitivity analyses combined with multivariable MR to identify robust associations. Genetic correlation analysis was applied to identify shared genetic risks.ResultsWe found genetically determined CRP was robustly associated with 15 diseases in the UK Biobank and 11 diseases in the FinnGen population (P
Deaths among people who have been fully vaccinated remain rare, but older adults and those with compromised immune systems are at much higher risk.
AbstractSecond-line treatment options for patients with relapsed, extensive-stage small cell lung cancer (ES-SCLC) are limited, and even with currently available treatments, prognosis remains poor. Until recently, topotecan (a topoisomerase I inhibitor) was the only drug approved by the United States (US) Food and Drug Administration (FDA) for the management of ES-SCLC following progression after first-line treatment with etoposide plus a platinum derivative (EP; carboplatin preferred). With the most recent approval of EP plus a prog rammed death ligand 1 (PD-L1) inhibitor, there are now more therapeutic options...
ConclusionThe dermatologist density in Bavaria correlates positively with the incidence of malignant melanoma. Despite an increased incidence, mortality was not elevated in the respective administrative regions.
Colin Powell, the first Black secretary of State and chairman of the Joint Chiefs of Staff, dies of COVID-19 complications after bout with blood cancer.
The WHO lists antimicrobial resistance as a top ten global health threat, saying that by 2050 it will kill more people than cancer. Could novel vaccines provide new ways to defeat superbugs?
Researchers from Durham University have developed a device that shines light directly into the brain through the skull, which they said could be a 'game-changer' in the fight against dementia.
Doctors say Colin Powell's age, his battle with multiple myeloma - a type of blood cancer - and Parkinson's contributed to his heightened risk of death from Covid despite being fully vaccinated.
Seattle-based Umoja Biopharma on Monday named Clay Siegall as chairman of its board of directors. Siegall is the CEO and co-founder of Bothell-based Seagen, a biotech company that went public on the Nasdaq in 2001. Siegall co-founded the company in 1998. "Clay's vast scientific training and wealth of experience, particularly his emphasis on targeted cancer therapies and ability to build a com pany from drug discovery to commercial-stage, will be a crucial part of Umoja's continued growth," Andy…
Medicare spent nearly $600 million over a three-year period for cancer care involving four Food and Drug Administration-approved drugs later found to provide no clinical benefit for certain forms of the disease.
Colin Powell had a form of blood cancer that saps natural immunity and also undermines the effects of vaccines like the ones used against Covid-19.